Skip to main content

Prostaglandin E2 EP receptors as therapeutic targets in breast cancer

Cancer and Metastasis Reviews volume 30, pages 449–463 (2011)Cite this article

Abstract

Prostaglandins are lipid compounds that mediate many physiological effects. Prostaglandin E2 (PGE2) is the most abundant prostanoid in the human body, and synthesis of PGE2 is driven by cyclooxygenase enzymes including COX-2. Both elevated expression of COX-2 and increased PGE2 levels have been associated with many cancers including breast cancer. PGE2 exerts its effect by binding to the E series of prostaglandin receptors (EP) which are G protein-coupled receptors. Four EP receptor subtypes exist, EP1–4, and each is coupled to different intracellular signaling pathways. As downstream effectors of the COX-2 pathway, EP receptors have been shown to play a role in breast and other malignancies and in cancer metastasis. The role of each EP receptor in malignant behavior is complex and involves the interplay of EP receptor signaling on the tumor cell, on stromal cells, and on host immune effector cells. While preclinical and epidemiological data support the use of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors (COXibs) for the prevention and treatment of malignancy, toxicities due to COXibs as well as less than promising results from clinical trials have laboratories seeking alternative targets. As knowledge concerning the role of EP receptors in cancer grows, so does the potential for exploiting EP receptors as therapeutic targets for the treatment or prevention of cancer and cancer metastasis.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Legler, D. F., Bruckner, M., Uetz-von Allmen, E., & Krause, P. (2010). Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. The International Journal of Biochemistry & Cell Biology, 42(2), 198–201.

    CAS  Google Scholar 

  2. Wang, M.-T., Honn, K. V., & Nie, D. (2007). Cyclooxygenases, prostanoids, and tumor progression. Cancer and Metastasis Reviews, 26(3–4), 525–534.

    PubMed  CAS  Google Scholar 

  3. Sugimoto, Y., & Narumiya, S. (2007). Prostaglandin E receptors. Journal of Biological Chemistry, 282(16), 11613–11617.

    PubMed  CAS  Google Scholar 

  4. Dannenberg, A. J., & Subbaramaiah, K. (2003). Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell, 4(6), 431–436.

    PubMed  CAS  Google Scholar 

  5. Kundu, N., Yang, Q., Dorsey, R., & Fulton, A. M. (2001). Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. International Journal of Cancer, 93(5), 681–686.

    CAS  Google Scholar 

  6. Greenhough, A., Smartt, H. J. M., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., et al. (2009). The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 30(3), 377–386.

    PubMed  CAS  Google Scholar 

  7. Menter, D. G., Schilsky, R. L., & DuBois, R. N. (2010). Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clinical Cancer Research, 16(5), 1384–1390.

    PubMed  CAS  Google Scholar 

  8. Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10(3), 181–193.

    PubMed  CAS  Google Scholar 

  9. Nakanishi, M., Gokhale, V., Meuillet, E. J., & Rosenberg, D. W. (2010). mPGES-1 as a target for cancer suppression: a comprehensive invited review “Phospholipase A2 and lipid mediators”. Biochimie, 92(6), 660–664.

    PubMed  CAS  Google Scholar 

  10. Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2010). Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis, 31(1), 37–49.

    PubMed  CAS  Google Scholar 

  11. Howe, L. R. (2007). Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Research, 9(4), 210.

    PubMed  Google Scholar 

  12. Howe, L. R., & Dannenberg, A. J. (2003). COX-2 inhibitors for the prevention of breast cancer. Journal of Mammary Gland Biology and Neoplasia, 8(1), 31–43.

    PubMed  Google Scholar 

  13. Ristimäki, A., Sivula, A., Lundin, J., Lundin, M., Salminen, T., Haglund, C., et al. (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Research, 62(3), 632–635.

    PubMed  Google Scholar 

  14. Singh, B., Berry, J. A., Shoher, A., Ayers, G. D., Wei, C., & Lucci, A. (2007). COX-2 involvement in breast cancer metastasis to bone. Oncogene, 26(26), 3789–3796.

    PubMed  CAS  Google Scholar 

  15. Liu, C. H., Chang, S. H., Narko, K., Trifan, O. C., Wu, M. T., Smith, E., et al. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. Journal of Biological Chemistry, 276(21), 18563–18569.

    PubMed  CAS  Google Scholar 

  16. Zerkowski, M. P., Camp, R. L., Burtness, B. A., Rimm, D. L., & Chung, G. G. (2007). Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Investigation, 25(1), 19–26.

    PubMed  CAS  Google Scholar 

  17. Chuah, B. Y. S., Putti, T., Salto-Tellez, M., Charlton, A., Iau, P., Buhari, S. A., et al. (2011). Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy. Annals of Oncology, 22(8), 1748–1754.

    PubMed  CAS  Google Scholar 

  18. Ranger, G. S., Thomas, V., Jewell, A., & Mokbel, K. (2004). Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Research, 24(4), 2349–2351.

    PubMed  CAS  Google Scholar 

  19. Ma, X., Yang, Q., Wilson, K. T., Kundu, N., Meltzer, S. J., & Fulton, A. M. (2004). Promoter methylation regulates cyclooxygenase expression in breast cancer. Breast Cancer Research, 6(4), R316–321.

    PubMed  CAS  Google Scholar 

  20. Kundu, N., & Fulton, A. M. (2002). Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Research, 62(8), 2343–2346.

    PubMed  CAS  Google Scholar 

  21. Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436(7050), 518–524.

    PubMed  CAS  Google Scholar 

  22. Bos, P. D., Zhang, X. H.-F., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., et al. (2009). Genes that mediate breast cancer metastasis to the brain. Nature, 459(7249), 1005–1009.

    PubMed  CAS  Google Scholar 

  23. Singh, B., Berry, J. A., Shoher, A., Ramakrishnan, V., & Lucci, A. (2005). COX-2 overexpression increases motility and invasion of breast cancer cells. International Journal of Oncology, 26(5), 1393–1399.

    PubMed  CAS  Google Scholar 

  24. Stasinopoulos, I., O’Brien, D. R., Wildes, F., Glunde, K., & Bhujwalla, Z. M. (2007). Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Molecular Cancer Research, 5(5), 435–442.

    PubMed  CAS  Google Scholar 

  25. Greenberg, E. R., Baron, J. A., Freeman, D. H., Jr., Mandel, J. S., & Haile, R. (1993). Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. Journal of the National Cancer Institute, 85(11), 912–916.

    PubMed  CAS  Google Scholar 

  26. Logan, R. F., Little, J., Hawtin, P. G., & Hardcastle, J. D. (1993). Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case–control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ, 307(6899), 285–289.

    PubMed  CAS  Google Scholar 

  27. Reeves, M. J., Newcomb, P. A., Trentham-Dietz, A., Storer, B. E., & Remington, P. L. (1996). Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiology, Biomarkers & Prevention, 5(12), 955–960.

    CAS  Google Scholar 

  28. Thun, M. J., Namboodiri, M. M., & Heath, C. W., Jr. (1991). Aspirin use and reduced risk of fatal colon cancer. The New England Journal of Medicine, 325(23), 1593–1596.

    PubMed  CAS  Google Scholar 

  29. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & DuBois, R. N. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107(4), 1183–1188.

    PubMed  CAS  Google Scholar 

  30. Kargman, S. L., O’Neill, G. P., Vickers, P. J., Evans, J. F., Mancini, J. A., & Jothy, S. (1995). Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Research, 55(12), 2556–2559.

    PubMed  CAS  Google Scholar 

  31. Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., et al. (1995). Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Research, 55(17), 3785–3789.

    PubMed  CAS  Google Scholar 

  32. Kutchera, W., Jones, D. A., Matsunami, N., Groden, J., McIntyre, T. M., Zimmerman, G. A., et al. (1996). Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proceedings of the National Academy of Sciences of the United States of America, 93(10), 4816–4820.

    PubMed  CAS  Google Scholar 

  33. Howe, L. R., Subbaramaiah, K., Brown, A. M., & Dannenberg, A. J. (2001). Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine-Related Cancer, 8(2), 97–114.

    PubMed  CAS  Google Scholar 

  34. Larkins, T. L., Nowell, M., Singh, S., & Sanford, G. L. (2006). Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer, 6, 181.

    PubMed  Google Scholar 

  35. Connolly, E. M., Harmey, J. H., O’Grady, T., Foley, D., Roche-Nagle, G., Kay, E., et al. (2002). Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. British Journal of Cancer, 87(2), 231–237.

    PubMed  CAS  Google Scholar 

  36. Friedman, G. D., & Ury, H. K. (1980). Initial screening for carcinogenicity of commonly used drugs. Journal of the National Cancer Institute, 65(4), 723–733.

    PubMed  CAS  Google Scholar 

  37. Harris, R. E., Chlebowski, R. T., Jackson, R. D., Frid, D. J., Ascenseo, J. L., Anderson, G., et al. (2003). Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Research, 63(18), 6096–6101.

    PubMed  CAS  Google Scholar 

  38. Harris, R. E., Namboodiri, K. K., & Farrar, W. B. (1996). Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology, 7(2), 203–205.

    PubMed  CAS  Google Scholar 

  39. Harris, R. E., Beebe-Donk, J., & Alshafie, G. A. (2006). Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer, 6, 27.

    PubMed  Google Scholar 

  40. Rahme, E., Ghosn, J., Dasgupta, K., Rajan, R., & Hudson, M. (2005). Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer, 5, 159.

    PubMed  Google Scholar 

  41. Holmes, M. D., Chen, W. Y., Li, L., Hertzmark, E., Spiegelman, D., & Hankinson, S. E. (2010). Aspirin intake and survival after breast cancer. Journal of Clinical Oncology, 28(9), 1467–1472.

    PubMed  CAS  Google Scholar 

  42. Ready, A., Velicer, C. M., McTiernan, A., & White, E. (2008). NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Research and Treatment, 109(3), 533–543.

    PubMed  CAS  Google Scholar 

  43. Khuder, S. A., & Mutgi, A. B. (2001). Breast cancer and NSAID use: a meta-analysis. British Journal of Cancer, 84(9), 1188–1192.

    PubMed  CAS  Google Scholar 

  44. Bosetti, C., Gallus, S., & La Vecchia, C. (2006). Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes & Control, 17(7), 871–888.

    Google Scholar 

  45. Mangiapane, S., Blettner, M., & Schlattmann, P. (2008). Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiology and Drug Safety, 17(2), 115–124.

    PubMed  Google Scholar 

  46. Takkouche, B., Regueira-Méndez, C., & Etminan, M. (2008). Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Journal of the National Cancer Institute, 100(20), 1439–1447.

    PubMed  CAS  Google Scholar 

  47. Valsecchi, M. E., Pomerantz, S. C., Jaslow, R., & Tester, W. (2009). Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors. Clinical Breast Cancer, 9(4), 225–230.

    PubMed  CAS  Google Scholar 

  48. Gill, J. K., Maskarinec, G., Wilkens, L. R., Pike, M. C., Henderson, B. E., & Kolonel, L. N. (2007). Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. American Journal of Epidemiology, 166(10), 1150–1158.

    PubMed  Google Scholar 

  49. Gierach, G. L., Lacey, J. V., Jr., Schatzkin, A., Leitzmann, M. F., Richesson, D., Hollenbeck, A. R., et al. (2008). Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Research, 10(2), R38.

    PubMed  Google Scholar 

  50. Zhang, S. M., Cook, N. R., Manson, J. E., Lee, I.-M., & Buring, J. E. (2008). Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. British Journal of Cancer, 98(5), 989–991.

    PubMed  CAS  Google Scholar 

  51. Jacobs, E. J., Thun, M. J., Bain, E. B., Rodriguez, C., Henley, S. J., & Calle, E. E. (2007). A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. Journal of the National Cancer Institute, 99(8), 608–615.

    PubMed  CAS  Google Scholar 

  52. Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., et al. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England Journal of Medicine, 352(11), 1092–1102.

    PubMed  CAS  Google Scholar 

  53. Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., et al. (2005). Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. The New England Journal of Medicine, 352(11), 1071–1080.

    PubMed  CAS  Google Scholar 

  54. Grosser, T., Fries, S., & FitzGerald, G. A. (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. The Journal of Clinical Investigation, 116(1), 4–15.

    PubMed  CAS  Google Scholar 

  55. Oldham, W. M., & Hamm, H. E. (2008). Heterotrimeric G protein activation by G-protein-coupled receptors. Nature Reviews Molecular Cell Biology, 9(1), 60–71.

    PubMed  CAS  Google Scholar 

  56. Lappano, R., & Maggiolini, M. (2011). G protein-coupled receptors: novel targets for drug discovery in cancer. Nature Reviews. Drug Discovery, 10(1), 47–60.

    PubMed  CAS  Google Scholar 

  57. Fulton, A. M., Ma, X., & Kundu, N. (2006). Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Research, 66(20), 9794–9797.

    PubMed  CAS  Google Scholar 

  58. Ichikawa, A., Sugimoto, Y., & Tanaka, S. (2010). Molecular biology of histidine decarboxylase and prostaglandin receptors. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 86(8), 848–866.

    PubMed  CAS  Google Scholar 

  59. Regan, J. W. (2003). EP2 and EP4 prostanoid receptor signaling. Life Sciences, 74(2–3), 143–153.

    PubMed  CAS  Google Scholar 

  60. Dey, I., Lejeune, M., & Chadee, K. (2006). Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. British Journal of Pharmacology, 149(6), 611–623.

    PubMed  CAS  Google Scholar 

  61. Fujino, H., & Regan, J. W. (2006). EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Molecular Pharmacology, 69(1), 5–10.

    PubMed  CAS  Google Scholar 

  62. Katoh, H., Watabe, A., Sugimoto, Y., Ichikawa, A., & Negishi, M. (1995). Characterization of the signal transduction of prostaglandin E receptor EP1 subtype in cDNA-transfected Chinese hamster ovary cells. Biochimica et Biophysica Acta, 1244(1), 41–48.

    PubMed  Google Scholar 

  63. Tabata, H., Tanaka, S., Sugimoto, Y., Kanki, H., Kaneko, S., & Ichikawa, A. (2002). Possible coupling of prostaglandin E receptor EP(1) to TRP5 expressed in Xenopus laevis oocytes. Biochemical and Biophysical Research Communications, 298(3), 398–402.

    PubMed  CAS  Google Scholar 

  64. Ji, R., Chou, C.-L., Xu, W., Chen, X.-B., Woodward, D. F., & Regan, J. W. (2010). EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway. Molecular Pharmacology, 77(6), 1025–1036.

    PubMed  CAS  Google Scholar 

  65. Voss, B., McLaughlin, J. N., Holinstat, M., Zent, R., & Hamm, H. E. (2007). PAR1, but not PAR4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis. Molecular Pharmacology, 71(5), 1399–1406.

    PubMed  CAS  Google Scholar 

  66. Okuda-Ashitaka, E., Sakamoto, K., Ezashi, T., Miwa, K., Ito, S., & Hayaishi, O. (1996). Suppression of prostaglandin E receptor signaling by the variant form of EP1 subtype. Journal of Biological Chemistry, 271(49), 31255–31261.

    PubMed  CAS  Google Scholar 

  67. Gomi, K., Zhu, F. G., & Marshall, J. S. (2000). Prostaglandin E2 selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colony-stimulating factor by mast cells through an EP1/EP3-dependent mechanism. Journal of Immunology, 165(11), 6545–6552.

    CAS  Google Scholar 

  68. Kotelevets, L., Foudi, N., Louedec, L., Couvelard, A., Chastre, E., & Norel, X. (2007). A new mRNA splice variant coding for the human EP3-I receptor isoform. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 77(3–4), 195–201.

    PubMed  CAS  Google Scholar 

  69. Israel, D. D., & Regan, J. W. (2009). EP(3) prostanoid receptor isoforms utilize distinct mechanisms to regulate ERK 1/2 activation. Biochimica et Biophysica Acta, 1791(4), 238–245.

    PubMed  CAS  Google Scholar 

  70. Kotani, M., Tanaka, I., Ogawa, Y., Usui, T., Mori, K., Ichikawa, A., et al. (1995). Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Molecular Pharmacology, 48(5), 869–879.

    PubMed  CAS  Google Scholar 

  71. Bilson, H. A., Mitchell, D. L., & Ashby, B. (2004). Human prostaglandin EP3 receptor isoforms show different agonist-induced internalization patterns. FEBS Letters, 572(1–3), 271–275.

    PubMed  CAS  Google Scholar 

  72. Jin, J., Mao, G. F., & Ashby, B. (1997). Constitutive activity of human prostaglandin E receptor EP3 isoforms. British Journal of Pharmacology, 121(2), 317–323.

    PubMed  CAS  Google Scholar 

  73. Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001). Prostanoid receptors: subtypes and signaling. Annual Review of Pharmacology and Toxicology, 41, 661–690.

    PubMed  CAS  Google Scholar 

  74. An, S., Yang, J., So, S. W., Zeng, L., & Goetzl, E. J. (1994). Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry, 33(48), 14496–14502.

    PubMed  CAS  Google Scholar 

  75. Schmid, A., Thierauch, K. H., Schleuning, W. D., & Dinter, H. (1995). Splice variants of the human EP3 receptor for prostaglandin E2. European Journal of Biochemistry, 228(1), 23–30.

    PubMed  CAS  Google Scholar 

  76. Hatae, N., Sugimoto, Y., & Ichikawa, A. (2002). Prostaglandin receptors: advances in the study of EP3 receptor signaling. Journal of Biochemistry, 131(6), 781–784.

    PubMed  CAS  Google Scholar 

  77. Sugimoto, Y., Negishi, M., Hayashi, Y., Namba, T., Honda, A., Watabe, A., et al. (1993). Two isoforms of the EP3 receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with Gi proteins. Journal of Biological Chemistry, 268(4), 2712–2718.

    PubMed  CAS  Google Scholar 

  78. Irie, A., Sugimoto, Y., Namba, T., Harazono, A., Honda, A., Watabe, A., et al. (1993). Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. European Journal of Biochemistry, 217(1), 313–318.

    PubMed  CAS  Google Scholar 

  79. Yamaoka, K., Yano, A., Kuroiwa, K., Morimoto, K., Inazumi, T., Hatae, N., et al. (2009). Prostaglandin EP3 receptor superactivates adenylyl cyclase via the Gq/PLC/Ca2+ pathway in a lipid raft-dependent manner. Biochemical and Biophysical Research Communications, 389(4), 678–682.

    PubMed  CAS  Google Scholar 

  80. Hatae, N., Yamaoka, K., Sugimoto, Y., Negishi, M., & Ichikawa, A. (2002). Augmentation of receptor-mediated adenylyl cyclase activity by Gi-coupled prostaglandin receptor subtype EP3 in a Gbetagamma subunit-independent manner. Biochemical and Biophysical Research Communications, 290(1), 162–168.

    PubMed  CAS  Google Scholar 

  81. Irie, A., Segi, E., Sugimoto, Y., Ichikawa, A., & Negishi, M. (1994). Mouse prostaglandin E receptor EP3 subtype mediates calcium signals via Gi in cDNA-transfected Chinese hamster ovary cells. Biochemical and Biophysical Research Communications, 204(1), 303–309.

    PubMed  CAS  Google Scholar 

  82. Zhu, T., Gobeil, F., Vazquez-Tello, A., Leduc, M., Rihakova, L., Bossolasco, M., et al. (2006). Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, and LPA1 receptors. Canadian Journal of Physiology and Pharmacology, 84(3–4), 377–391.

    PubMed  CAS  Google Scholar 

  83. Gobeil, F., Fortier, A., Zhu, T., Bossolasco, M., Leduc, M., Grandbois, M., et al. (2006). G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Canadian Journal of Physiology and Pharmacology, 84(3–4), 287–297.

    PubMed  CAS  Google Scholar 

  84. Gobeil, F., Jr., Vazquez-Tello, A., Marrache, A. M., Bhattacharya, M., Checchin, D., Bkaily, G., et al. (2003). Nuclear prostaglandin signaling system: biogenesis and actions via heptahelical receptors. Canadian Journal of Physiology and Pharmacology, 81(2), 196–204.

    PubMed  CAS  Google Scholar 

  85. Gobeil, F., Jr., Dumont, I., Marrache, A. M., Vazquez-Tello, A., Bernier, S. G., Abran, D., et al. (2002). Regulation of eNOS expression in brain endothelial cells by perinuclear EP(3) receptors. Circulation Research, 90(6), 682–689.

    PubMed  CAS  Google Scholar 

  86. Bhattacharya, M., Peri, K., Ribeiro-da-Silva, A., Almazan, G., Shichi, H., Hou, X., et al. (1999). Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. Journal of Biological Chemistry, 274(22), 15719–15724.

    PubMed  CAS  Google Scholar 

  87. Bhattacharya, M., Peri, K. G., Almazan, G., Ribeiro-da-Silva, A., Shichi, H., Durocher, Y., et al. (1998). Nuclear localization of prostaglandin E2 receptors. Proceedings of the National Academy of Sciences of the United States of America, 95(26), 15792–15797.

    PubMed  CAS  Google Scholar 

  88. Thorat, M. A., Morimiya, A., Mehrotra, S., Konger, R., & Badve, S. S. (2008). Prostanoid receptor EP1 expression in breast cancer. Modern Pathology, 21(1), 15–21.

    PubMed  CAS  Google Scholar 

  89. Ma, X., Kundu, N., Ioffe, O. B., Goloubeva, O., Konger, R., Baquet, C., et al. (2010). Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Molecular Cancer Research, 8(10), 1310–1318.

    PubMed  CAS  Google Scholar 

  90. Han, C., Demetris, A. J., Stolz, D. B., Xu, L., Lim, K., & Wu, T. (2006). Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway. Journal of Biological Chemistry, 281(34), 24831–24846.

    PubMed  CAS  Google Scholar 

  91. Rolland, P. H., Martin, P. M., Jacquemier, J., Rolland, A. M., & Toga, M. (1980). Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. Journal of the National Cancer Institute, 64(5), 1061–1070.

    PubMed  CAS  Google Scholar 

  92. Bennett, A., Charlier, E. M., McDonald, A. M., Simpson, J. S., Stamford, I. F., & Zebro, T. (1977). Prostaglandins and breast cancer. Lancet, 2(8039), 624–626.

    PubMed  CAS  Google Scholar 

  93. Tan, W. C., Privett, O. S., & Goldyne, M. E. (1974). Studies of prostaglandins in rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene. Cancer Research, 34(12), 3229–3231.

    PubMed  CAS  Google Scholar 

  94. Chang, S.-H., Liu, C. H., Conway, R., Han, D. K., Nithipatikom, K., Trifan, O. C., et al. (2004). Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 101(2), 591–596.

    PubMed  CAS  Google Scholar 

  95. Chang, S.-H., Ai, Y., Breyer, R. M., Lane, T. F., & Hla, T. (2005). The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Research, 65(11), 4496–4499.

    PubMed  CAS  Google Scholar 

  96. Chang, S.-H., Liu, C. H., Wu, M.-T., & Hla, T. (2005). Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor. Prostaglandins & Other Lipid Mediators, 76(1–4), 48–58.

    CAS  Google Scholar 

  97. Tian, M., & Schiemann, W. P. (2010). PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. The FASEB Journal, 24(4), 1105–1116.

    PubMed  CAS  Google Scholar 

  98. Subbaramaiah, K., Hudis, C., Chang, S. H., Hla, T., & Dannenberg, A. J. (2008). EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. Journal of Biological Chemistry, 283(6), 3433–3444.

    PubMed  CAS  Google Scholar 

  99. Richards, J. A., & Brueggemeier, R. W. (2003). Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. Journal of Clinical Endocrinology and Metabolism, 88(6), 2810–2816.

    PubMed  CAS  Google Scholar 

  100. Zhao, Y., Agarwal, V. R., Mendelson, C. R., & Simpson, E. R. (1996). Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology, 137(12), 5739–5742.

    PubMed  CAS  Google Scholar 

  101. Han, E. H., Kim, H. G., Hwang, Y. P., Choi, J. H., Im, J. H., Park, B., et al. (2010). The role of cyclooxygenase-2-dependent signaling via cyclic AMP response element activation on aromatase up-regulation by o,p′-DDT in human breast cancer cells. Toxicology Letters, 198(3), 331–341.

    PubMed  CAS  Google Scholar 

  102. Subbaramaiah, K., Howe, L. R., Bhardwaj, P., Du, B., Gravaghi, C., Yantiss, R. K., et al. (2011). Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prevention Research (Philadelphia, Pa.), 4(3), 329–346.

    CAS  Google Scholar 

  103. Robertson, F. M., Simeone, A.-M., Mazumdar, A., Shah, A. H., McMurray, J. S., Ghosh, S., et al. (2008). Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. Journal of Experimental Therapeutics and Oncology, 7(4), 299–312.

    PubMed  CAS  Google Scholar 

  104. Robertson, F. M., Simeone, A.-M., Lucci, A., McMurray, J. S., Ghosh, S., & Cristofanilli, M. (2010). Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer, 116(11 Suppl), 2806–2814.

    PubMed  CAS  Google Scholar 

  105. Blindt, R., Bosserhoff, A.-K., vom Dahl, J., Hanrath, P., Schrör, K., Hohlfeld, T., et al. (2002). Activation of IP and EP(3) receptors alters cAMP-dependent cell migration. European Journal of Pharmacology, 444(1–2), 31–37.

    PubMed  CAS  Google Scholar 

  106. Amano, H., Hayashi, I., Endo, H., Kitasato, H., Yamashina, S., Maruyama, T., et al. (2003). Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. The Journal of Experimental Medicine, 197(2), 221–232.

    PubMed  CAS  Google Scholar 

  107. Taniguchi, T., Fujino, H., Israel, D. D., Regan, J. W., & Murayama, T. (2008). Human EP3(I) prostanoid receptor induces VEGF and VEGF receptor-1 mRNA expression. Biochemical and Biophysical Research Communications, 377(4), 1173–1178.

    PubMed  CAS  Google Scholar 

  108. Kubo, H., Hosono, K., Suzuki, T., Ogawa, Y., Kato, H., Kamata, H., et al. (2010). Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis. Biomedicine and Pharmacotherapy, 64(2), 101–106.

    CAS  Google Scholar 

  109. Timoshenko, A. V., Chakraborty, C., Wagner, G. F., & Lala, P. K. (2006). COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. British Journal of Cancer, 94(8), 1154–1163.

    PubMed  CAS  Google Scholar 

  110. Tober, K. L., Wilgus, T. A., Kusewitt, D. F., Thomas-Ahner, J. M., Maruyama, T., & Oberyszyn, T. M. (2006). Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. The Journal of Investigative Dermatology, 126(1), 205–211.

    PubMed  CAS  Google Scholar 

  111. Bai, X.-M., Jiang, H., Ding, J.-X., Peng, T., Ma, J., Wang, Y.-H., et al. (2010). Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells. Life Sciences, 86(5–6), 214–223.

    PubMed  CAS  Google Scholar 

  112. Kawamori, T., Uchiya, N., Nakatsugi, S., Watanabe, K., Ohuchida, S., Yamamoto, H., et al. (2001). Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis, 22(12), 2001–2004.

    PubMed  CAS  Google Scholar 

  113. Chandramouli, A., Mercado-Pimentel, M. E., Hutchinson, A., Gibadulinová, A., Olson, E. R., Dickinson, S., et al. (2010). The induction of S100p expression by the Prostaglandin E2 (PGE2)/EP4 receptor signaling pathway in colon cancer cells. Cancer Biology & Therapy, 10(10), 1056–1066.

    CAS  Google Scholar 

  114. Cherukuri, D. P., Chen, X. B. O., Goulet, A.-C., Young, R. N., Han, Y., Heimark, R. L., et al. (2007). The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Experimental Cell Research, 313(14), 2969–2979.

    PubMed  CAS  Google Scholar 

  115. Yang, L., Huang, Y., Porta, R., Yanagisawa, K., Gonzalez, A., Segi, E., et al. (2006). Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Research, 66(19), 9665–9672.

    PubMed  CAS  Google Scholar 

  116. Oshima, H., Popivanova, B. K., Oguma, K., Kong, D., Ishikawa, T. O., & Oshima, M. (2011). Activation of epidermal growth factor receptor signaling by the prostaglandin E(2) receptor EP4 pathway during gastric tumorigenesis. Cancer Science, 102(4), 713–719.

    PubMed  CAS  Google Scholar 

  117. Terada, N., Shimizu, Y., Kamba, T., Inoue, T., Maeno, A., Kobayashi, T., et al. (2010). Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Research, 70(4), 1606–1615.

    PubMed  CAS  Google Scholar 

  118. Zheng, Y., Ritzenthaler, J. D., Sun, X., Roman, J., & Han, S. (2009). Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1. Cancer Research, 69(3), 896–904.

    PubMed  CAS  Google Scholar 

  119. Kim, J. I., Lakshmikanthan, V., Frilot, N., & Daaka, Y. (2010). Prostaglandin E2 promotes lung cancer cell migration via EP4-βArrestin1-c-Src signalsome. Molecular Cancer Research, 8(4), 569–577.

    PubMed  CAS  Google Scholar 

  120. Timoshenko, A., Guoxiong, X., CHakrabarti, S., Lala, P., & Chakraborty, C. (2003). Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Experimental Cell Research, 289, 265–274.

    PubMed  CAS  Google Scholar 

  121. Timoshenko, A. V., Lala, P. K., & Chakraborty, C. (2004). PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors. International Journal of Cancer, 108(3), 384–389.

    CAS  Google Scholar 

  122. Jadeski, L. C., Chakraborty, C., & Lala, P. K. (2002). Role of nitric oxide in tumour progression with special reference to a murine breast cancer model. Canadian Journal of Physiology and Pharmacology, 80(2), 125–135.

    PubMed  CAS  Google Scholar 

  123. Ohshiba, T., Miyaura, C., & Ito, A. (2003). Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. Biochemical and Biophysical Research Communications, 300(4), 957–964.

    PubMed  CAS  Google Scholar 

  124. Pan, M.-R., Hou, M.-F., Chang, H.-C., & Hung, W.-C. (2008). Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. Journal of Biological Chemistry, 283(17), 11155–11163.

    PubMed  CAS  Google Scholar 

  125. Subbaramaiah, K., Benezra, R., Hudis, C., & Dannenberg, A. J. (2008). Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription. Journal of Biological Chemistry, 283(49), 33955–33968.

    PubMed  CAS  Google Scholar 

  126. Ma, X., Kundu, N., Rifat, S., Walser, T., & Fulton, A. M. (2006). Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Research, 66(6), 2923–2927.

    PubMed  CAS  Google Scholar 

  127. Kundu, N., Ma, X., Holt, D., Goloubeva, O., Ostrand-Rosenberg, S., & Fulton, A. M. (2009). Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Research and Treatment, 117(2), 235–242.

    PubMed  CAS  Google Scholar 

  128. Choudhry, M., Ahmed, Z., & Sayeed, M. (1999). PGE(2)-mediated inhibition of T-cell p59 (fyn) is independent of cAMP. American Journal of Physiology, 277(2Pt1), C301–C309.

    Google Scholar 

  129. Harris, S., Padilla, J., Koumas, L., Ray, D., & Phipps, R. (2002). Prostaglandins as modulators of immunity. Trends in Immunology, 23(3), 144–150.

    PubMed  CAS  Google Scholar 

  130. Choudhry, M., Hockberger, P., & Sayeed, M. (1999). PGE2 suppresses mitogen-induced Ca2+ mobilization in T cells. American Journal of Physiology, 277(6Pt2), R17410–R1748.

    Google Scholar 

  131. Porter, B., & Malek, T. (1999). Prostaglandin E2 inhibits T-cell activation-induced apoptosis and Fas-mediated cellular cytotoxicity by blockade of Fas-ligand induction. European Journal of Immunology, 29(7), 2360–2365.

    PubMed  CAS  Google Scholar 

  132. Hilkens, C., Snijders, A., Snijdewint, F., Wierenga, E., & Kapsenberg, M. (1996). Modulation of T-cell cytokine secretion by accessory-cell-derived products. European Respiratory Journal Supplement, 22, 90s–94s.

    CAS  Google Scholar 

  133. Garrone, P., Galibert, L., Rousset, F., Fu, S., & Branchereau, J. (1994). Regulatory effects of prostaglandin E2 on the growth and differentiation of human B lymphocytes activated through their CD40 antigen. Journal of Immunology, 152(9), 4282–4290.

    CAS  Google Scholar 

  134. Brown, D., Warner, G., Ales-Marinez, S., Scott, D., & Phipps, R. (1992). Prostaglandin E2 induces apoptosis in immature normal and malignant B lymphocytes. Clinical Immunology and Immunopathology, 63(3), 221–229.

    PubMed  CAS  Google Scholar 

  135. Roper, R., Brown, D., & Phipps, R. (1995). Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE. The Journal of Immunology, 154, 162–170.

    PubMed  CAS  Google Scholar 

  136. Ikegami, R., Sugimoto, Y., Segi, E., Katsuyama, M., Karahashi, H., Amano, F., et al. (2001). The expression of prostaglandin E2 receptors EP2 and EP4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages. The Journal of Immunology, 166(7), 4689–4696.

    PubMed  CAS  Google Scholar 

  137. Voiculescu, C., Rosu, L., & Rogoz, S. (1988). Modulation of mouse spleen natural killer (NK) cell activity by beta-interferon, interleukin-1, and prostaglandins. Lymphology, 21, 144–151.

    PubMed  CAS  Google Scholar 

  138. Brunda, M. J., Herberman, R. B., & Holden, H. T. (1980). Inhibition of murine natural killer cell activity by prostaglandin. The Journal of Immunology, 124(6), 2682–2687.

    PubMed  CAS  Google Scholar 

  139. Bankhurst, A. (1982). The modulation of human natural killer cell activity by prostaglandins. Journal of Clinical & Laboratory Immunology, 7, 85–91.

    CAS  Google Scholar 

  140. Baxevanis, C., Reclos, G., Gritzapis, A., Dedousis, G., Missitzis, I., & Papamichail, M. (1993). Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer, 72(2), 491–501.

    PubMed  CAS  Google Scholar 

  141. Fulton, A. (1988). Inhibition of experimental metastasis with indomethacin: role of macrophages and natural killer cells. Prostaglandins, 35(3), 413–425.

    PubMed  CAS  Google Scholar 

  142. Su, Y., Huang, X., Raskovalova, T., Zacharia, L., Lokshin, A., Jackson, E., et al. (2008). Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunology and Immunotherapeutics, 57, 1611–1623.

    CAS  Google Scholar 

  143. Su, Y., Jackson, E., & Gorelik, E. (2011). Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunology and Immunotherapy, 60(1), 111–122.

    CAS  Google Scholar 

  144. Holt, D., Ma, X., Kundu, N., Fulton, A., (2011). Prostaglandin E2 (PGE2) suppresses natural killer cell function through the PGE2 receptor EP4. Cancer Immunology and Immunotherapy. doi:10.1007/s00262-011-1064-9.

  145. Nataraj, C., Thomas, D., Tilley, S., Nguyen, M., Mannon, R., Koller, B., et al. (2001). Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse. The Journal of Clinical Investigation, 108(8), 1229–1235.

    PubMed  CAS  Google Scholar 

  146. Yao, C., Sakata, D., Esaki, Y., Li, Y., Matsuoka, T., Kuroiwa, K., et al. (2009). Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nature Medicine, 15(6), 633–640.

    PubMed  CAS  Google Scholar 

  147. Boniface, K., Bak-Jensen, K., Li, Y., Blumenschein, W., McGeachy, M., McClanahan, T., et al. (2009). Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. The Journal of Experimental Medicine, 206(3), 535–548.

    PubMed  CAS  Google Scholar 

  148. Sharma, S., Yang, S., Zhu, L., Reckamp, K., Gardner, B., Baratelli, F., et al. (2005). Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Research, 65(12), 5211–5220.

    PubMed  CAS  Google Scholar 

  149. Fedyk, E., & Phipps, R. (1996). Prostaglandin E2 receptors of the EP2 and EP4 subtype regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proceedings of the National Academy of Sciences, 93, 10978–10983.

    CAS  Google Scholar 

  150. Panzer, U., & Uguccioni, M. (2004). Prostaglandin E2 modulates the functional responsiveness of human monocytes to chemokines. European Journal of Immunology, 34(12), 3682–3689.

    PubMed  CAS  Google Scholar 

  151. De Vries, G., Guarino, P., McLaughlin, A., Chen, J., Andrews, S., & Woodward, D. (1995). An EP receptor with a novel pharmacological profile in the T-cell line Jurkat. British Journal of Pharmacology, 115, 1231–1234.

    PubMed  Google Scholar 

  152. Fedyk, E., Ripper, J., Brown, D., & Phipps, R. (1996). A molecular analysis of PGE receptor (EP) expression on normal and transformed B lymphocytes: coexpression of EP1, EP2, EP3β, EP4. Molecular Immunology, 33(1), 33–45.

    PubMed  CAS  Google Scholar 

  153. Sinha, P., Clements, V. K., Fulton, A. M., & Ostrand-Rosenberg, S. (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Research, 67(9), 4507–4513.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work is supported by the United States Department of Health and Human Services, United States Department of Defense, United States Department of Veteran Affairs, and Susan G. Komen for the Cure.

Author information

Affiliations

  1. University of Maryland Marlene and Stewart Greenebaum Cancer Center, 655 W. Baltimore, St, Baltimore, MD, 21201, USA

    Jocelyn Reader & Amy Fulton

  2. Department of Pathology, University of Maryland School of Medicine, Baltimore, USA

    Jocelyn Reader, Dawn Holt & Amy Fulton

  3. Baltimore Veterans Administration, Baltimore, USA

    Amy Fulton

Authors
  1. Jocelyn Reader
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dawn Holt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amy Fulton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy Fulton.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Reader, J., Holt, D. & Fulton, A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 30, 449–463 (2011). https://doi.org/10.1007/s10555-011-9303-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-011-9303-2

Keywords

  • Prostaglandin
  • Cyclooxygenase
  • Cancer
  • EP receptors